

# [Always and Never: Words not meant for the practice of medicine, the laboratory, or a pandemic](#)

written by CAP TODAY  
February 16, 2022

As a first-year medical student, once a week my small group would meet with an attending physician to learn how to talk to patients respectfully and document that conversation in the history and physical examination. In those early years of medical school, my time was mostly spent in lecture halls, gross anatomy and microanatomy labs, and the library studying, so these weekly meetings held all the promise and anticipation of what practicing medicine and actually treating patients would bring. In one of those meetings, our leader made a comment that had a lasting impression: the words “always” and “never” have no place in the dialogue of strong science and the practice of good medicine. Always and never. Two words at opposite ends of a spectrum that imply absolute certainty.



©2026 CAP TODAY, all rights reserved.

---

## [FDA clears Streck MDx-Chex for BCID2](#)

written by CAP TODAY  
February 16, 2022

Jan. 31, 2022—Streck’s MDx-Chex for BCID2, a quality control designed to meet the standards for verifying the performance of the BioFire BCID2 panel assay for sepsis, has been granted FDA clearance for in vitro diagnostics use.



©2026 CAP TODAY, all rights reserved.

---

## **Biodesix launches GeneStrat NGS, IQLung testing strategy**

written by CAP TODAY  
February 16, 2022

Jan. 28, 2022—Biodesix announced the launch of its GeneStrat NGS genomic test, a blood-based tumor profiling test.



©2026 CAP TODAY, all rights reserved.

---

## **Siemens launches Enhanced Liver Fibrosis test in U.S.**

written by CAP TODAY  
February 16, 2022

Jan. 26, 2022—Siemens Healthineers' Enhanced Liver Fibrosis test is now available in the United States.



©2026 CAP TODAY, all rights reserved.

---

# [Siemens SARS-CoV-2 testing portfolio detects omicron](#)

written by CAP TODAY  
February 16, 2022

January 2022—Siemens Healthineers announced that the company's SARS-CoV-2 tests are designed to detect the omicron variant. The company evaluated the potential impact of the variant on the Clinitest Rapid COVID-19 antigen test; the FTD SARS-CoV-2 assay, a PCR test; and the Atellica IM/Advia Centaur SARS-CoV-2 antigen assay (CoV2Ag). To assess the potential impact of the Clinitest rapid test and the CoV2Ag assay, Siemens' R&D team analyzed the sequence data of the omicron variant nucleocapsid protein, which demonstrated greater than 98 percent sequence homology of the nucleocapsid protein to other SARS-CoV-2 variants. The Clinitest Rapid COVID-19 Antigen Self-Test has a sensitivity of 97.25 percent and a specificity of 100 percent compared with a PCR, or nucleic acid-detection method, and provides results in 15 minutes.



©2026 CAP TODAY, all rights reserved.

---

# [Bio-Rad adds SARS-CoV-2 S gene delta-kappa variants control](#)

written by CAP TODAY  
February 16, 2022

January 2022—Bio-Rad Laboratories launched its Exact Diagnostics SARS-CoV-2 S Gene Delta-Kappa Variants Control for research testing. The control includes lineages B.1.617.1, B.1.617.2 (AY sublineages), and B.1.617.3. The product is an addition to the company's SARS-CoV-2 S gene variants controls alpha, beta, epsilon, and gamma, which were released in August.



## [LumiraDx, Audere offer at-home self-collection kit](#)

written by CAP TODAY  
February 16, 2022

January 2022—LumiraDx announced a partnership with digital health nonprofit Audere to offer a COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV-2 RNA Star Complete assay to process self-collected samples. SARS-CoV-2 RNA Star Complete has received FDA emergency use authorization for use by authorized laboratories. Laboratories using SARS-CoV-2 RNA Star Complete will be able to integrate Audere's HealthPulse@home into their systems.



## [Streck launches QC for sepsis](#)

written by CAP TODAY  
February 16, 2022

January 2022—Streck announced the availability of its MDx-Chex for BCID2 quality control, designed to meet the standards for verifying the performance of sample-to-result molecular tests for sepsis.



---

## [Co-Diagnostics to acquire Idaho Molecular, Advanced Conceptions](#)

written by CAP TODAY  
February 16, 2022

January 2022—Co-Diagnostics has entered into definitive agreements with Idaho Molecular and Advanced Conceptions in which both companies will become wholly owned subsidiaries of Co-Dx. Salt Lake City-based Co-Dx has been working with Idaho Molecular and Advanced Conceptions on the development of Co-Dx's at-home, point-of-care diagnostic device. The transactions will provide Co-Dx with existing and future assets and intellectual property related to the platform.



©2026 CAP TODAY, all rights reserved.

---

## [Seegene PCR test IDs omicron, VOCs in one tube](#)

written by CAP TODAY  
February 16, 2022

January 2022—Seegene unveiled the Novaplex SARS-CoV-2 Variants VII assay for research use only. The assay identifies positive COVID-19 cases and distinguishes between alpha, beta, gamma, delta, and omicron and its stealth version. The RT-PCR test targets five analytes including the *RdRP* gene and three omicron S-gene mutations, E484A, N501Y, HV69/70 deletion. It also targets endogenous internal controls, which serve as a control to verify specimen validity.



©2026 CAP TODAY, all rights reserved.